CloneID: MCAF5352A (Afasevikumab)
Heavy Chain modification: Fc Silent™
Antigen Long Description: The original antibody was produced by immunizing HuMab® mice with human IL-17.
Origin Pub PMID: 31779513
Buffer Composition: PBS only.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for human IL-17A and human IL-17F. It also binds their respective dimers — IL-17AA, IL-17AF, and IL-17FF.
Application Notes (Clone): This antibody successfully completed phase I clinical trials (Mitra et al., 2014; PMID: 25398489). The pharmacokinetics of this antibody and the post-dose levels of IL-17AA and IL-17FF in healthy were assessed as part of the phase I study (Peng et al., 2018; PMID: 30547287). The crystal structure of the Fab version of this antibody was resolved, and its binding kinetics (KD) was measured at 7.78 ± 0.23 pM. Furthermore, alterations to the antibody's aromatic residues in its binding site and their effect on binding kinetics were assessed (Tilegenova et al., 2020; PMID: 31779513).
Deutsch
English
